Development and characterization of novel toxoplasma gondii inhibitors

Abstract

Toxoplasma gondii</italic> is an obligate intracellular, protozoan parasite of the phylum Apicomplexa. While the parasite relies on the feline to complete its life-cycle, many mammals can contract the infection. In humans, infection can cause serious illness or death. Treatments currently available are limited by toxicity and teratogenicity. This necessitates the development of novel drug compounds. Tryptanthrin and its analogue, 8-bromotryptanthrin, have shown promise in the treatment of <italic>Toxoplasma gondii in vitro</italic>. New tryptanthrin derivatives were synthesized, characterized, and tested for efficacy and toxicity. These compounds show a structure-activity relationship at the 8-position and low toxicity.